Am J Transplant, Volume 18, Suppl 3 Archives - Page 75 of 211 - ATC Abstracts

2018 American Transplant Congress
The Incidence and Risk Factors for Non – Adherence to Medical Treatment among Patients after Kidney Transplantation
T. Mashraki,^1,2,3 B. Rozen-Zvi,^1,4 E. Mor,^2,4 A. Yussim,^1,2 C. Avry,^1,4 R. Rahamimov.^1,2,3
¹Nephrology and Hypertension, Rabin Medical Center, Petach Tikva, Israel; ²Transplantation, Rabin Medical Center, Petach Tikva, Israel; ³Faculty of Health Science, Ariel University Center of Samaria, Ariel, Israel; ⁴Sackler Faculty of Medicine, Tel- Aviv University, Tel- Aviv, Israel.
Background: Nonadherence to medical treatment is an important risk factor for acute rejection and graft loss. In this study we sought to determine the prevalence…
2018 American Transplant Congress
The Impact of the Influenza Vaccine on Pediatric Kidney Transplant Outcomes
M. Camerino,¹ S. Jackson,² S. Chinnakotla,³ P. Verghese.¹
¹Department of Pediatrics, University of Minnesota, Minneapolis, MN; ²Fairview Health Services, Minneapolis, MN; ³Department of Surgery, University of Minnesota, Minneapolis, MN.
The influenza vaccine has been associated with de novo DSA and rejection in adult kidney recipients. This risk has not been adequately assessed in pediatric…
2018 American Transplant Congress
Impact of Once-Daily Tacrolimus on Adherence in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss,¹ J. Goebel,² M. Bock.²
¹Pharmacy, Children's Hospital Colorado, Aurora, CO; ²Pediatric Nephrology, Children's Hospital Colorado, Aurora, CO.
Medication non-adherence is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs), especially adolescents and young adults (AYA). Number of medication…
2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…
2018 American Transplant Congress
Validating MORAL in Living Donor Liver Transplantation for Hepatocellular Carcinoma
A. Bhatti, A. Qureshi, N. Khan, M. Butt, A. Waheed, A. Rana, F. Dar.
Hepatobiliary Surgery and Liver Transplantation, Hepatology, Radiology, Shifa International Hospital, Islamabad, Pakistan.
The “Model of Recurrence after Liver Transplant” (MORAL) study has identified certain pre and post operative variables that have significant impact on recurrence free survival…
2018 American Transplant Congress
A Long-Term Experience with Expansion of Milan Criteria for Liver Transplant Recipients
S. Commander,¹ B. Shaw,¹ L. Washburn,² D. Yoeli,² A. Rana,² J. Goss.²
¹Duke University, Durham, NC; ²Baylor College of Medicine, Houston, TX.
Background: The Milan Criteria (MC) have historically determined eligibility for transplantation for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) Region 4 expanded…
2018 American Transplant Congress
Wait Times for Pediatric Liver Transplantation and the Impact of PELD/MELD Exception
K. Khan,¹ C. Desai,² F. Thomas,¹ K. Alexander.¹
¹Transplant Institute, MedStar Georgetown University Hospital, Washington, DC; ²Surgery, University of North Carolina, Chapel Hill, NC.
Background:In order to even the playing field for patients without liver disease that nevertheless are in urgent need for a liver graft the United Network…
2018 American Transplant Congress
Evaluation and Cost Burden of Inappropriately Drawn Immunosuppression Trough Levels in the Acute Care Setting at an Academic Medical Center
A. Brown, J. Geyston, A. Agarwal, B. Jones, W. Ally.
University of Virginia Health System, Charlottesville, VA.
Trough drug levels in narrow therapeutic index medications, such as CNI and mTOR inhibitors are used to estimate total drug exposure. Inappropriately measured trough levels…
2018 American Transplant Congress
What Happened When the 'Soft Opt-Out' to Organ Donation Was Implemented in Wales? Family and Professional Views and Experiences, and Consent Rates for the First 18 Months
L. Mc Laughlin, J. Noyes, K. Morgan, P. Walton, A. Roberts, M. Stephens.
Social Sciences, Bangor University, Bangor, Wales, United Kingdom; Major Health Conditions Policy Team, Welsh Government, Cardiff, Wales, United Kingdom; Organ Donation, NHS Blood and Transplant, Cardiff and Liverpool, Wales, United Kingdom; Nephrology and Transplantation, University Hospital of Wales, Cardiff, Wales, United Kingdom.
On 01.12.15 Wales introduced a 'soft opt-out' system of organ donation.Co-productive, mixed-methods study partnered with NHS Blood and Transplant and patient and public representatives. Data…
2018 American Transplant Congress
Medicare Part D Plans Deny Coverage for Off-Label and Off-Compendia Immunosuppressant Use: A Case Series
L. Potter, E. Garrity.
Pharmacy, University of Chicago Medicine, Chicago, IL; Pulmonary & Critical Care Medicine, University of Chicago Medicine, Chicago, IL.
Immunosuppressants are a protected drug class under the Medicare Part D benefit, meaning that all drugs in this class must be present on all plan…